Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: May 2, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NCI CTEP-Approved Trials for the Month of April

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I

9771: Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in Patients with Refractory Solid Tumors. National Cancer Institute Developmental Therapeutics Clinic; Chen, A. P. (301) 496-4291

 

9898: A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor. City of Hope Comprehensive Cancer Center LAO; Riess, Jonathan W. (916) 734-3772

 

9903: A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor. Dana-Farber - Harvard Cancer Center LAO; Oxnard, Geoffrey Raymond. (617) 632-6049

 

Phase II

ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial. Children’s Oncology Group; Armenian, Saro H. (626) 471-7320

 

EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN). ECOG-ACRIN Cancer Research Group; Ferris, Robert Louis. (412) 623-1416

 

S1500: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET). SWOG; Pal, Sumanta Kumar. (626) 256-4673

 

Other Phases

AAML15B7-Q: Comparison of Molecular Features of Pediatric CML and Adult CML. Children’s Oncology Group; Sakamoto, Kathleen Miho. (650) 725-9250

 

AAML15B8-Q: Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia. Children’s Oncology Group; Aplenc, Richard. (267) 426-7252

 

AAML15B9-Q: Nox4 Inhibition as a Therapeutic Target in FLT3/ITD+ AML. Children’s Oncology Group; Metts, Jonathan Layne. (404) 727-3246

 

AAML16B1-Q: Identification and Development of Biomarker Profiles to Predict Clinical Outcomes for Acute Myeloid Leukemia (AML) Patients with NPM1pos/FLT3-ITDneg Genotype. Children’s Oncology Group; Stirewalt, Derek Lynn. (206) 667-5386

 

AEWS15B2-Q: Prognostic Significance of STAG2 Loss and TP53 Mutations in Ewing Sarcoma. Children’s Oncology Group; Crompton, Brian. (617) 632-4468

 

NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Study. ECOG-ACRIN Cancer Research Group; Sekeres, Mikkael Aaron. (216) 445-9353



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter